Model averaging for robust assessment of QT prolongation by concentration-response analysis-Reference-Cited by-同舟云学术

Model averaging for robust assessment of QT prolongation by concentration-response analysis

Published:2017-07-13 Issue:24 Volume:36 Page:3844-3857
ISSN:0277-6715
Container-title:Statistics in Medicine
language:en
Short-container-title:Statistics in Medicine

Author:

Dosne A.G.¹^ORCID,Bergstrand M.¹,Karlsson M.O.¹,Renard D.²,Heimann G.²

Affiliation:

1. Uppsala University; Uppsala Sweden

2. Novartis Pharma AG; Basel Switzerland

Publisher

Wiley

Subject

Statistics and Probability,Epidemiology

Reference27 articles.

1. International Conference on Harmonisation E14: guidance on clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs 2005

2. Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine;Chapel;Clin Pharmacol Ther,2010

3. Performance characteristics for some typical QT study designs under the ICH E-14 guidance;Hutmacher;J Clin Pharmacol,2008

4. The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies;Bouvy;Clin Pharmacol Ther,2012

5. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review;Garnett;J Clin Pharmacol,2008

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of model‐integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods;CPT: Pharmacometrics & Systems Pharmacology;2024-08-28

2. Assessment of non-linear mixed effects model-based approaches to test for drug effect using simulated data: type I error and power properties;2024-04-17

3. Comparison of Seven Non-Linear Mixed Effect Model-Based Approaches to Test for Treatment Effect;Pharmaceutics;2023-01-30

4. Assessing Treatment Effects with Pharmacometric Models: A New Method that Addresses Problems with Standard Assessments;The AAPS Journal;2021-05

5. Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidates;Journal of Pharmacokinetics and Pharmacodynamics;2019-10-30